Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Cellectar Biosciences (DE:NV4)
FRANKFURT:NV4
RESEARCH TOOLSreports
Cellectar Biosciences (NV4) Stock Price & Analysis
0 Followers
NV4 Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€1.24 - €3.88
Previous Close€3.28
Volume0.00
Average Volume (3M)2.75K
Market Cap
€100.88M
Enterprise Value€92.40M
Total Cash (Recent Filing)$9.56M
Total Debt (Recent Filing)$552.98K
Price to Earnings (P/E)N/A
Beta2.00
Next Earnings
May 06, 2024EPS Estimate
-€0.46Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding32,260,510
10 Day Avg. Volume150
30 Day Avg. Volume2,748
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)-41.36
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-3.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-2.93
Forecast
1Y Price Target
€14.71Price Target Upside348.59% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Cellectar Biosciences News
Options Prices
Currently, No data available
---
Ownership Overview
0.00% Insiders
0.00% Mutual Funds
24.31% Other Institutional Investors
75.69% Public Companies and
Individual Investors
NV4 FAQ
What was Cellectar Biosciences’s price range in the past 12 months?
Cellectar Biosciences lowest stock price was €1.24 and its highest was €3.88 in the past 12 months.
What is Cellectar Biosciences’s market cap?
Currently, no data Available
When is Cellectar Biosciences’s upcoming earnings report date?
Cellectar Biosciences’s upcoming earnings report date is May 06, 2024 which is in 10 days.
How were Cellectar Biosciences’s earnings last quarter?
Cellectar Biosciences released its earnings results on Mar 27, 2024. The company reported -€0.386 earnings per share for the quarter, beating the consensus estimate of -€0.537 by €0.151.
Is Cellectar Biosciences overvalued?
According to Wall Street analysts Cellectar Biosciences’s price is currently Undervalued.
Does Cellectar Biosciences pay dividends?
Cellectar Biosciences does not currently pay dividends.
What is Cellectar Biosciences’s EPS estimate?
Cellectar Biosciences’s EPS estimate is -€0.46.
How many shares outstanding does Cellectar Biosciences have?
Currently, no data Available
What happened to Cellectar Biosciences’s price movement after its last earnings report?
Cellectar Biosciences reported an EPS of -€0.386 in its last earnings report, beating expectations of -€0.537. Following the earnings report the stock price went down -2.874%.
Which hedge fund is a major shareholder of Cellectar Biosciences?
Among the largest hedge funds holding Cellectar Biosciences’s share is Consonance Capital. It holds Cellectar Biosciences’s shares valued at N/A.
---
Cellectar Biosciences Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€14.71 (348.59% Upside)
€14.71 (348.59% Upside)
Blogger Sentiment
Bullish
DE:NV4 Sentiment 100%
Sector Average 70%
Sector Average 70%
Technicals
SMA
Positive
20 days / 200 days
Momentum
137.14%
12-Months-Change
Fundamentals
Return on Equity
-536.81%
Trailing 12-Months
Asset Growth
-44.07%
Trailing 12-Months
Company Description
Cellectar Biosciences
Cellectar BioSciences, Inc. engages in the development of phospholipid drug conjugates (PDCs) for the treatment and imaging of cancer. Its portfolio includes CLR 131, which seeks to treat relapse or refractory multiple myeloma; CLR 125, which intends to treat micro metastatic disease; CLR 124 which could detects tumors and metastases in a broad range of cancers; and CLR 1502, a cancer-targeting near-infrared-fluorophore optical imaging PDC for intraoperative tumor and tumor margin illumination. The company was founded in June,1996 and is headquartered in Florham Park, NJ.
---
NV4 Earnings Call
Q4 2024
0:00 / 0:00
---
NV4 Stock 12 Months Forecast
Average Price Target
€14.71
▲(348.59% Upside)
Technical Analysis
Cellectar Biosciences
―
Clearside Biomedical
―
Traws Pharma
―
Citius Pharmaceuticals
―
Akebia Therapeutics
―
Best Analysts Covering NV4
1 Year
1 Year Success Rate
7/10 ratings generated profit
1 Year Average Return
+40.82%
reiterated a buy rating last month
Copying Jason McCarthy's trades and holding each position for 1 Year would result in 70.00% of your transactions generating a profit, with an average return of +40.82% per trade.
---